

# Oncology Medication Clinical Coverage

Guideline Number: MMG094.N  
 Effective Date: February 1, 2021

[➔ Instructions for Use](#)

Table of Contents	Page
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Applicable Codes</a> .....	2
<a href="#">Background</a> .....	3
<a href="#">Benefit Considerations</a> .....	4
<a href="#">References</a> .....	4
<a href="#">Guideline History/Revision Information</a> .....	5
<a href="#">Instructions for Use</a> .....	5

Related Clinical Guideline
<ul style="list-style-type: none"> <li><a href="#">Chimeric Antigen Receptor T-cell Therapy</a></li> </ul>

## Coverage Rationale

[➔ See Benefit Considerations](#)

### Description

This policy provides parameters for coverage of injectable oncology medications (including, but not limited to octreotide acetate, leuprolide acetate, leucovorin and levoleucovorin) including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium® (NCCN Compendium®). The Compendium lists the appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. Each commendation is supported by a level of evidence category. This policy does not provide coverage criteria for Chimeric Antigen Receptor (CAR)-T Cell products. Coverage determinations are based on the member’s benefits and OptumHealth Transplant Solutions criteria for covered transplants, refer to the Clinical Guideline titled [Chimeric Antigen Receptor T-cell Therapy](#)

### Coverage Rationale

The Oncology Products table below lists the UnitedHealthcare West (UHCWest) preferred oncology products and respective non-preferred products. Coverage will be provided for the UHCWest preferred oncology product contingent on the coverage criteria in the [Diagnosis-Specific Criteria](#) section.

Coverage for any respective non-preferred oncology product will be provided contingent on the criteria in the [Preferred Product Criteria](#) and the [Diagnosis-Specific Criteria](#) sections. Members new to therapy will be required to utilize the UHCWest preferred oncology product unless they meet the criteria in this section.

### Preferred Product Criteria

Treatment with the respective non-preferred product specified in the [Oncology Products](#) table below is medically necessary for oncology indications when both of the following are met:

- History of intolerance or contraindication to the UHCWest preferred oncology product; and
- Physician attests that, in their clinical opinion, the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product.

## Oncology Products

Below are UHCWest preferred oncology products with therapeutically equivalent and/or biosimilar\* non-preferred products as determined by the United Healthcare Pharmacy & Therapeutics (P&T) Committee:

UnitedHealthcare Preferred Oncology Product(s)	UnitedHealthcare Non-Preferred Oncology Product(s)
Mvasi (bevacizumab-awwb)	Avastin (bevacizumab) Zirabev (bevacizumab-bvzr)
Kanjinti (trastuzumab-anns) Trazimera (trastuzumab-qyyp)	Herceptin (trastuzumab) Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Herzuma (trastuzumab-pkrb) Ogivri (trastuzumab-dkst) Ontruzant (trastuzumab-dttb)
Kanjinti (trastuzumab-anns) + Perjeta (pertuzumab) Phesgo (pertuzumab, trastuzumab, hyaluronidase-zzxf)* * Trazimera (trastuzumab-qyyp) + Perjeta (pertuzumab)	Herceptin (trastuzumab) + Perjeta (pertuzumab) Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) + Perjeta (pertuzumab) Herzuma (trastuzumab-pkrb) + Perjeta (pertuzumab) Ogivri (trastuzumab-dkst) + Perjeta (pertuzumab) Ontruzant (trastuzumab-dttb) + Perjeta (pertuzumab)
Ruxience (rituximab-pvvr) Truxima (rituximab-abbs)	Rituxan (rituximab) Rituxan Hycela (rituximab/hyaluronidase human, recombinant)
Gemcitabine	Infugem (gemcitabine in sodium chloride injection)
Leucovorin	Levoleucovorin
Eligard, Lupron, Lupron Depot, Supprelin LA, Trelstar, Vantas, Zoladex	Lupron Depot-Ped

\*Biosimilar means that the biological product is FDA-approved based on data demonstrating that it is highly similar to an already FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.

\*\* Phesgo is a combination product of pertuzumab + trastuzumab.

### Diagnosis-Specific Criteria

#### Injectable Oncology Medications

UnitedHealthcare West recognizes indications and uses of injectable oncology medications, including therapeutic radiopharmaceuticals, listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary and Categories of Evidence and Consensus of 3 as unproven and not medically necessary.

UnitedHealthcare West will cover all chemotherapy agents for individuals under the age of 19 years for oncology indications. The majority of pediatric patients receive treatments on national pediatric protocols that are quite similar in concept to the NCCN patient care guidelines.

Refer to [Preferred Product Criteria](#) for the UHC West preferred oncology products that have therapeutically equivalent and/or biosimilar products available.

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws

that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
J0640	Injection, leucovorin calcium, per 50 mg
J0641	Injection, levoleucovorin, not otherwise specified, 0.5 mg
J0642	Injection, levoleucovorin (khapzory), 0.5 mg
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg
J3315	Injection, triptorelin pamoate, 3.75 mg
J9035	Injection, bevacizumab, 10 mg
J9198	Injection, gemcitabine hydrochloride, (infugem), 100 mg
J9199	Injection, gemcitabine hydrochloride (infugem), 200 mg
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J9202	Goserelin acetate implant, per 3.6 mg
J9217	Leuprolide acetate (for depot suspension), 7.5 mg
J9218	Leuprolide acetate injection
J9219	Leuprolide acetate implant, 65 mg
J9310	Injection, rituximab, 100 mg
J9312	Injection, rituximab, 10 mg
J9355	Injection, trastuzumab, 10 mg
J9356	Injection, trastuzumab, 10 mg and Hyaluronidase-oysk
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5112	Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
Q5113	Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
Q5114	Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
Q5115	Injection, rituximab-abbs, biosimilar, 10 mg
Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

## Background

The NCCN Clinical Practice Guidelines in Oncology™ (NCCN Guidelines®) are comprehensive guidelines documenting management decisions and interventions that apply to malignancies which apply to more than 97% cancers affecting U.S. patients.

### NCCN Categories of Evidence and Consensus

- Category 1: The recommendation is based on high-level evidence (i.e., high-powered randomized clinical trials or meta-analyses), and the panel has reached uniform consensus that the recommendation is indicated. In this context, uniform means near unanimous positive support with some possible neutral positions.
- Category 2A: The recommendation is based on lower level evidence, but despite the absence of higher level studies, there is uniform consensus that the recommendation is appropriate. Lower level evidence is interpreted broadly, and runs the gamut from phase II to large cohort studies to case series to individual practitioner experience. Importantly, in many instances, the retrospective studies are derived from clinical experience of treating large numbers of patients at a member institution, so panel members have first-hand knowledge of the data. Inevitably, some recommendations must address clinical situations for which limited or no data exist. In these instances the congruence of experience-based opinions

provides an informed if not confirmed direction for optimizing patient care. These recommendations carry the implicit recognition that they may be superseded as higher level evidence becomes available or as outcomes-based information becomes more prevalent.

- Category 2B: The recommendation is based on lower level evidence, and there is nonuniform consensus that the recommendation should be made. In these instances, because the evidence is not conclusive, institutions take different approaches to the management of a particular clinical scenario. This nonuniform consensus does not represent a major disagreement, rather it recognizes that given imperfect information, institutions may adopt different approaches. A Category 2B designation should signal to the user that more than one approach can be inferred from the existing data.
- Category 3: The recommendation has engendered a major disagreement among the panel members. Several circumstances can cause major disagreements. For example, if substantial data exist about two interventions but they have never been directly compared in a randomized trial, adherents to one set of data may not accept the interpretation of the other side's results. Another situation resulting in a Category 3 designation is when experts disagree about how trial data can be generalized. A Category 3 designation alerts users to a major interpretation issue in the data and directs them to the manuscript for an explanation of the controversy.

Therapeutic radiopharmaceuticals [e.g., Azedra® (iobenguane I 131), Lutathera® (lutetium Lu 177 dotatate), Xofigo® (radium-223)] used to treat cancer are medications that contain radioactive material. The radioactive agent selectively accumulates within the tumor releasing radiation which then kills cancer cells.

## Benefit Considerations

If the coverage review using the NCCN Compendium determines that the drug is unproven, then further review is indicated. Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The Member-specific benefit document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances. Some states also mandate usage of other Compendium references. Where such mandates apply, they supersede language in the benefit document or in the drug policy.

Chimeric Antigen Receptor (CAR)-T Cell Therapy may be eligible for coverage as an autologous stem cell therapy under a member's Transplantation Services benefit. Coverage determinations are based on the OptumHealth Transplant Solutions criteria for covered transplants; refer to the Clinical Guideline titled [Chimeric Antigen Receptor T-cell Therapy](#)

## References

1. The NCCN Drugs and Biologics Compendium (NCCN Compendium®)  
[http://www.nccn.org/professionals/drug\\_compendium/content/contents.asp](http://www.nccn.org/professionals/drug_compendium/content/contents.asp)
2. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
3. Pazdur R. Endpoints for assessing drug activity in clinical trials. *Oncologist*. 2008;13 Suppl 2:19-21.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst*. 2000 Feb 2;92(3):205-16.
5. Center for Drug Evaluation and Research. Biosimilars. Retrieved from <https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars>

## Guideline History/Revision Information

Date	Summary of Changes														
02/01/2021	<p><b>Coverage Rationale</b></p> <ul style="list-style-type: none"> <li>Updated reference link to the Optum criteria for covered transplants with Chimeric Antigen Receptor (CAR)-T Cell products; replaced “<i>Transplant Review Guidelines: Hematopoietic Stem Cell Transplantation</i>” with “<i>Clinical Guideline: Chimeric Antigen Receptor T-cell Therapy</i>”</li> <li>Revised list of preferred oncology products with therapeutically equivalent and/or biosimilar non-preferred oncology products:           <ul style="list-style-type: none"> <li>Changed Trazimera (trastuzumab-qyyp) from a non-preferred product to a preferred product</li> <li>Added:               <table border="1" data-bbox="435 478 1490 926"> <thead> <tr> <th data-bbox="435 478 964 520">Preferred Oncology Product</th> <th data-bbox="964 478 1490 520">Non-Preferred Oncology Product</th> </tr> </thead> <tbody> <tr> <td data-bbox="435 520 964 590">Kanjinti (trastuzumab-anns) + Perjeta (pertuzumab)</td> <td data-bbox="964 520 1490 590">Herceptin (trastuzumab) + Perjeta (pertuzumab)</td> </tr> <tr> <td data-bbox="435 590 964 722">Phesgo (pertuzumab, trastuzumab, hyaluronidase-zzxf) [Phesgo is a combination product of pertuzumab + trastuzumab]</td> <td data-bbox="964 590 1490 659">Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) + Perjeta (pertuzumab)</td> </tr> <tr> <td data-bbox="435 722 964 791">Trazimera (trastuzumab-qyyp) + Perjeta (pertuzumab)</td> <td data-bbox="964 659 1490 728">Herzuma (trastuzumab-pkrb) + Perjeta (pertuzumab)</td> </tr> <tr> <td data-bbox="435 791 964 856"></td> <td data-bbox="964 728 1490 798">Ogivri (trastuzumab-dkst) + Perjeta (pertuzumab)</td> </tr> <tr> <td data-bbox="435 856 964 926">Eligard, Lupron, Lupron Depot, Supprelin LA, Trelstar, Vantas, Zoladex</td> <td data-bbox="964 798 1490 867">Ontruzant (trastuzumab-dttb) + Perjeta (pertuzumab)</td> </tr> <tr> <td data-bbox="435 926 964 926"></td> <td data-bbox="964 867 1490 926">Lupron Depot-Ped</td> </tr> </tbody> </table> </li> </ul> </li> </ul> <p><b>Applicable Codes</b></p> <ul style="list-style-type: none"> <li>Removed notation indicating the denied drug codes apply to all outpatient places of service (including office, hospital, etc.)</li> <li>Added HCPCS codes J0640, J0641, J0642, J1950, J3315, J9035, J9198, J9199, J9201, J9202, J9217, J9218, J9310, J9312, J9355, J9356, Q5107, Q5112, Q5113, Q5114, Q5115, Q5116, Q5117, Q5118, and Q5119</li> </ul> <p><b>Benefit Considerations</b></p> <ul style="list-style-type: none"> <li>Updated reference link to the Optum criteria for covered transplants with Chimeric Antigen Receptor (CAR)-T Cell Therapy; replaced “<i>Transplant Review Guidelines: Hematopoietic Stem Cell Transplantation</i>” with “<i>Clinical Guideline: Chimeric Antigen Receptor T-cell Therapy</i>”</li> </ul> <p><b>Supporting Information</b></p> <ul style="list-style-type: none"> <li>Archived previous policy version MMG094.M</li> </ul>	Preferred Oncology Product	Non-Preferred Oncology Product	Kanjinti (trastuzumab-anns) + Perjeta (pertuzumab)	Herceptin (trastuzumab) + Perjeta (pertuzumab)	Phesgo (pertuzumab, trastuzumab, hyaluronidase-zzxf) [Phesgo is a combination product of pertuzumab + trastuzumab]	Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) + Perjeta (pertuzumab)	Trazimera (trastuzumab-qyyp) + Perjeta (pertuzumab)	Herzuma (trastuzumab-pkrb) + Perjeta (pertuzumab)		Ogivri (trastuzumab-dkst) + Perjeta (pertuzumab)	Eligard, Lupron, Lupron Depot, Supprelin LA, Trelstar, Vantas, Zoladex	Ontruzant (trastuzumab-dttb) + Perjeta (pertuzumab)		Lupron Depot-Ped
Preferred Oncology Product	Non-Preferred Oncology Product														
Kanjinti (trastuzumab-anns) + Perjeta (pertuzumab)	Herceptin (trastuzumab) + Perjeta (pertuzumab)														
Phesgo (pertuzumab, trastuzumab, hyaluronidase-zzxf) [Phesgo is a combination product of pertuzumab + trastuzumab]	Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) + Perjeta (pertuzumab)														
Trazimera (trastuzumab-qyyp) + Perjeta (pertuzumab)	Herzuma (trastuzumab-pkrb) + Perjeta (pertuzumab)														
	Ogivri (trastuzumab-dkst) + Perjeta (pertuzumab)														
Eligard, Lupron, Lupron Depot, Supprelin LA, Trelstar, Vantas, Zoladex	Ontruzant (trastuzumab-dttb) + Perjeta (pertuzumab)														
	Lupron Depot-Ped														

## Instructions for Use

This Medical Management Guideline provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this guideline, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Management Guideline is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare West Medical Management Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Member benefit coverage and limitations may vary based on the member's benefit plan Health Plan coverage provided by or through UnitedHealthcare of California, UnitedHealthcare Benefits Plan of California, UnitedHealthcare of Oklahoma, Inc., UnitedHealthcare of Oregon, Inc., UnitedHealthcare Benefits of Texas, Inc., or UnitedHealthcare of Washington, Inc.